Lineage Cell Therapeutics DEF 14A: Executive Compensation Details
Ticker: LCTX · Form: DEF 14A · Filed: Apr 29, 2025 · CIK: 876343
| Field | Detail |
|---|---|
| Company | Lineage Cell Therapeutics, Inc. (LCTX) |
| Form Type | DEF 14A |
| Filed Date | Apr 29, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, equity-awards, sec-filing
Related Tickers: LCTX
TL;DR
Lineage Cell Therapeutics DEF 14A out: Executive pay & stock awards for 2022-2024 detailed.
AI Summary
Lineage Cell Therapeutics, Inc. filed a DEF 14A on April 29, 2025, detailing executive compensation and equity awards for the fiscal years ending December 31, 2022, 2023, and 2024. The filing includes information on changes in the fair value of outstanding equity awards and awards granted in prior years that vested during the covered years for both principal executive officers (PEO) and non-principal executive officers (Non-PEO).
Why It Matters
This filing provides transparency into how Lineage Cell Therapeutics compensates its top executives, which can influence investor perception and decisions regarding the company's financial health and management.
Risk Assessment
Risk Level: medium — DEF 14A filings related to executive compensation can sometimes reveal insights into company performance and future outlook, potentially impacting stock price.
Key Numbers
- 2022-2024 — Fiscal Years Covered (Executive compensation and equity award data reported for these years.)
Key Players & Entities
- Lineage Cell Therapeutics, Inc. (company) — Filer of the DEF 14A
- BIOTIME INC (company) — Former company name
- 20250429 (date) — Filing date
- 20250626 (date) — Conformed period of report
- 1231 (date) — Fiscal year end
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose is to provide detailed information regarding the compensation of Lineage Cell Therapeutics, Inc.'s top executives and directors, as well as details on equity awards.
What specific periods does this filing cover regarding compensation data?
This filing covers compensation data for the fiscal years ending December 31, 2022, 2023, and 2024.
What type of equity awards are detailed in the filing?
The filing details changes in the fair value of outstanding and unvested equity awards granted in prior years, as well as equity awards that vested during the covered years.
Who are the categories of individuals for whom compensation data is provided?
Compensation data is provided for Principal Executive Officers (PEO) and Non-Principal Executive Officers (Non-PEO).
When was this DEF 14A filing submitted to the SEC?
This DEF 14A filing was submitted to the SEC on April 29, 2025.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 29, 2025 regarding Lineage Cell Therapeutics, Inc. (LCTX).